Arbutus Biopharma (ABUS) Gains from Investment Securities (2010 - 2026)
Arbutus Biopharma's (ABUS) quarterly Gains from Investment Securities came in at $209000.0 in Q1 2026, down 30.1% year-on-year from $299000.0 in Q1 2025, and up 107.95% quarter-over-quarter from -$2.6 million in Q4 2025.
Arbutus Biopharma (ABUS) Gains from Investment Securities (2010 - 2026) Analysis & Trends
Arbutus Biopharma has disclosed Gains from Investment Securities across 17 years of filings, most recently posting $209000.0 for Q1 2026.
- Gains from Investment Securities for Q1 2026 came in at $209000.0, down 30.1% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.9 million (down 1713.45% YoY), and the FY2025 annual result was -$1.8 million, changed N/A from the prior year.
- Gains from Investment Securities came in at $209000.0 for Q1 2026 at Arbutus Biopharma, up from -$2.6 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $344000.0 in Q3 2024 to a low of -$2.6 million in Q4 2025.
- The 5-year median for Gains from Investment Securities is $205000.0 (2023), against an average of -$94176.5.
- Across the five-year window, Gains from Investment Securities soared 990.0% in 2023 and slumped 512.92% in 2024, its largest moves.
- Arbutus Biopharma's Gains from Investment Securities stood at -$20000.0 in 2022, then jumped by 990.0% to $178000.0 in 2023, then plunged by 512.92% to -$735000.0 in 2024, then slumped by 257.82% to -$2.6 million in 2025, then soared by 107.95% to $209000.0 in 2026.
- The last three Gains from Investment Securities figures came in at $209000.0 (Q1 2026), -$2.6 million (Q4 2025), and $241000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Arbutus Biopharma | 882.62 Mn | 882.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 209,000.00 |
| Mar 31, 2026 | 209,000.00 |
| Dec 31, 2025 | -2.63 Mn |
| Dec 31, 2025 | -2.63 Mn |
| Sep 30, 2025 | 241,000.00 |
| Sep 30, 2025 | 241,000.00 |
| Jun 30, 2025 | 260,000.00 |
| Jun 30, 2025 | 260,000.00 |
| Mar 31, 2025 | 299,000.00 |
| Mar 31, 2025 | 299,000.00 |
| Dec 31, 2024 | -735,000.00 |
| Dec 31, 2024 | -735,000.00 |
| Sep 30, 2024 | 344,000.00 |
| Sep 30, 2024 | 344,000.00 |
| Jun 30, 2024 | 211,000.00 |
| Jun 30, 2024 | 211,000.00 |
| Mar 31, 2024 | 180,000.00 |
| Mar 31, 2024 | 180,000.00 |
| Dec 31, 2023 | 178,000.00 |
| Dec 31, 2023 | 178,000.00 |